Kaposi's sarcoma-associated herpesvirus kaposin B induces unique monophosphorylation of STAT3 at serine 727 and MK2-mediated inactivation of the STAT3 transcriptional repressor TRIM28

Journal of Virology

Volumn 87, Issue 15, 2013, Pages 8779-8791

  King, Christine ^a  

^a State University of New York Upstate Medical University: College of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEAT SHOCK PROTEIN 27; INTERLEUKIN 6; KAPOSIN B PROTEIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; RANTES; REGULATOR PROTEIN; SERINE; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 3; TRIPARTITE MOTIF CONTAINING PROTEIN 28; TYROSINE; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ARTICLE; CCL5 GENE; CHRONIC INFLAMMATION; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVATION; GENE; GENE ACTIVATION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN HERPESVIRUS 8; IN VITRO STUDY; INTERLEUKIN 6 GENE; INTRACELLULAR SIGNALING; KAPOSI SARCOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN TARGETING; PROTO ONCOGENE; SKIN CARCINOGENESIS; SOCS3 GENE; TRANSCRIPTION REGULATION; VIRUS CELL INTERACTION; VIRUS PATHOGENESIS;

CELLS, CULTURED; ENDOTHELIAL CELLS; HERPESVIRUS 8, HUMAN; HOST-PATHOGEN INTERACTIONS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; PROTEIN-SERINE-THREONINE KINASES; REPRESSOR PROTEINS; STAT3 TRANSCRIPTION FACTOR; VIRAL PROTEINS;

EID: 84880611418     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02976-12     Document Type: Article

References (87)

1. Boshoff C, Schulz TF, Kennedy MM, Graham AK, Fisher C, Thomas A, McGee JO, Weiss RA, O'Leary JJ. 1995. Kaposi's sarcoma-associated herpesvirus infects endothelial and spindle cells. Nat. Med. 1:1274-1278.
2. Cesarman E, Chang Y, Moore PS, Said JW, Knowles DM. 1995. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N. Engl. J. Med. 332:1186-1191.
3. Soulier J, Grollet L, Oksenhendler E, Cacoub P, Cazals-Hatem D, Babinet P, d'Agay MF, Clauvel JP, Raphael M, Degos L, Sigaux F. 1995. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in mu ticentric Castleman's disease. Blood 86:1276-1280
4. Boshoff C, Weiss RA. 1998. Kaposi's sarcoma-associated herpesvirus. Adv. Cancer Res. 75:57-86.
5. Dupin N, Fisher C, Kellam P, Ariad S, Tulliez M, Franck N, van Marck E, Salmon D, Gorin I, Escande JP, Weiss RA, Alitalo K, Boshoff C. 1999. Distribution of human herpesvirus-8 latently infected cells in Kaposi's sarcoma, multicentric Castleman's disease, and primary effusion lymphoma. Proc. Natl. Acad. Sci. U. S. A. 96:4546-4551.
6. Boshoff C, Weiss RA. 1997. Aetiology of Kaposi's sarcoma: current understanding and implications for therapy. Mol. Med. Today 3:488-494.
7. Ensoli B, Nakamura S, Salahuddin SZ, Biberfeld P, Larsson L, Beaver B, Wong-Staal F, Gallo RC. 1989. AIDS-Kaposi's sarcoma-derived cells express cytokines with autocrine and paracrine growth effects. Science 243:223-226.
8. Sodhi A, Montaner S, Patel V, Zohar M, Bais C, Mesri EA, Gutkind S. 2000. The Kaposi's sarcoma-associated herpes virus G protein-coupled receptor up-regulates vascular endothelial growth factor expression and secretion through mitogen-activated protein kinase and p38 pathways acting on hypoxia-inducible factor 1alpha. Cancer Res. 60:4873-4880.
9. Staskus KA, Zhong W, Gebhard K, Herndier B, Wang H, Renne R, Beneke J, Pudney J, Anderson DJ, Ganem D, Haase AT. 1997. Kaposi's sarcoma-associated herpesvirus gene expression in endothelial (spindle) tumor cells. J. Virol. 71:715-719.
10. McCormick C, Ganem D. 2005. The kaposin B protein of KSHV activates the p38/MK2 pathway and stabilizes cytokine mRNAs. Science 307:739-741.
11. Catlett-Falcone R, Dalton WS, Jove R. 1999. STAT proteins as novel targets for cancer therapy. Signal transducer an activator of transcription. Curr. Opin. Oncol. 11:490-496.
12. Grivennikov S, Karin E, Terzic J, Mucida D, Yu GY, Vallabhapurapu S, Scheller J, Rose-John S, Cheroutre H, Eckmann L, Karin M. 2009. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 15:103-113.
13. Kujawski M, Kortylewski M, Lee H, Herrmann A, Kay H, Yu H. 2008. Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice. J. Clin. Invest. 118:3367-3377.
14. Levy DE, Darnell JE, Jr. 2002. Stats: transcriptional control and biological impact. Nat. Rev. Mol. Cell Biol. 3:651-662.
15. Mantovani A, Allavena P, Sica A, Balkwill F. 2008. Cancer-related inflammation. Nature 454:436-444.
16. Mantovani A, Marchesi F, Portal C, Allavena P, Sica A. 2008. Linking inflammation reactions to cancer: novel targets for therapeutic strategies. Adv. Exp. Med. Biol. 610:112-127.
17. Yu LF, Zhu YB, Qiao MM, Zhong J, Tu SP, Wu YL. 2004. Constitutive activation and clinical significance of Stat3 in human gastric cancer tissues and cell lines. Zhonghua Yi Xue Za Zhi 84:2064-2069. (In Chinese.)
18. Bowman T, Garcia R, Turkson J, Jove R. 2000. STATs in oncogenesis. Oncogene 19:2474-2488.
19. Chen CL, Hsieh FC, Lieblein JC, Brown J, Chan C, Wallace JA, Cheng G, Hall BM, Lin J. 2007. Stat3 activation in human endometrial and cervical cancers. Br. J. Cancer 96:591-599.
20. Garcia R, Jove R. 1998. Activation of STAT transcription factors in oncogenic tyrosine kinase signaling. J. Biomed. Sci. 5:79-85.
21. Mora LB, Buettner R, Seigne J, Diaz J, Ahmad N, Garcia R, Bowman T, Falcone R, Fairclough R, Cantor A, Muro-Cacho C, Livingston S, Karras J, Pow-Sang J, Jove R. 2002. Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. Cancer Res. 62:6659-6666.
22. Turkson J. 2004. STAT proteins as novel targets for cancer drug discovery. Expert Opin. Ther. Targets 8:409-422.
23. Turkson J, Jove R. 2000. STAT proteins: novel molecular targets for cancer drug discovery. Oncogene 19:6613-6626.
24. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C, Darnell JE, Jr. 1999. Stat3 as an oncogene. Cell 98:295-303.
25. Grandis JR, Drenning SD, Zeng Q, Watkins SC, Melhem MF, Endo S, Johnson DE, Huang L, He Y, Kim JD. 2000. Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. Proc. Natl. Acad. Sci. U. S. A. 97:4227-4232.
26. Niu G, Wright KL, Huang M, Song L, Haura E, Turkson J, Zhang S, Wang T, Sinibaldi D, Coppola D, Heller R, Ellis LM, Karras J, Bromberg J, Pardoll D, Jove R, Yu H. 2002. Constitutive Stat3 activity upregulates VEGF expression and tumor angiogenesis. Oncogene 21:2000-2008.
27. Wang T, Niu G, Kortylewski M, Burdelya L, Shain K, Zhang S, Bhattacharya R, Gabrilovich D, Heller R, Coppola D, Dalton W, Jove R, Pardoll D, Yu H. 2004. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat. Med. 10:48-54.
28. Yu H, Jove R. 2004. The STATs of cancer-new molecular targets come of age. Nat. Rev. Cancer 4:97-105.
29. Aoki Y, Feldman GM, Tosato G. 2003. Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. Blood 101:1535-1542.
30. Punjabi AS, Carroll PA, Chen L, Lagunoff M. 2007. Persistent activation of STAT3 by latent Kaposi's sarcoma-associated herpesvirus infection of endothelial cells. J. Virol. 81:2449-2458.
31. Darnell JE, Jr, Kerr IM, Stark GR. 1994. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science. 264:1415-1421.
32. Zhong Z, Wen Z, Darnell JE, Jr. 1994. Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science. 264:95-98.
33. Wen Z, Zhong Z, Darnell JE, Jr. 1995. Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation. Cell. 82:241-250.
34. Cimica V, Chen HC, Iyer JK, Reich NC. 2011. Dynamics of the STAT3 transcription factor: nuclear import dependent on Ran and importinbeta1. PLoS One 6:e20188. doi:10.1371/journal.pone.0020188.
35. Liu L, McBride KM, Reich NC. 2005. STAT3 nuclear import is independent of tyrosine phosphorylation and mediated by importin-alpha3. Proc. Natl. Acad. Sci. U. S. A.. 102:8150-8155.
36. Yang J, Liao X, Agarwal MK, Barnes L, Auron PE, Stark GR. 2007. Unphosphorylated STAT3 accumulates in response to IL-6 and activates transcription by binding to NFkappaB. Genes Dev.. 21:1396-1408.
37. Hazan-Halevy I, Harris D, Liu Z, Liu J, Li P, Chen X, Shanker S, Ferrajoli A, Keating MJ, Estrov Z. 2010. STAT3 is constitutively phosphorylated on serine 727 residues, binds DNA, and activates transcription in CLL cells. Blood. 115:2852-2863.
38. Friedman JR, Fredericks WJ, Jensen DE, Speicher DW, Huang XP, Neilson EG, Rauscher FJ, III. 1996. KAP-1, a novel corepressor for the highly conserved KRAB repression domain. Genes Dev.. 10:2067-2078.
39. Tsuruma R, Ohbayashi N, Kamitani S, Ikeda O, Sato N, Muromoto R, Sekine Y, Oritani K, Matsuda T. 2008. Physical and functional interactions between STAT3 and KAP1. Oncogene. 27:3054-3059.
40. Nielsen AL, Ortiz JA, You J, Oulad-Abdelghani M, Khechumian R, Gansmuller A, Chambon P, Losson R. 1999. Interaction with members of the heterochromatin protein 1 (HP1) family and histone deacetylation are differentially involved in transcriptional silencing by members of the TIF1 family. EMBO J.. 18:6385-6395.
41. Schultz DC, Ayyanathan K, Negorev D, Maul GG, Rauscher FJ, III. 2002. SETDB1: a novel KAP-1-associated histone H3, lysine 9-specific methyltransferase that contributes to HP1-mediated silencing of euchromatic genes by KRAB zinc-finger proteins. Genes Dev.. 16:919-932.
42. Chang CW, Chou HY, Lin YS, Huang KH, Chang CJ, Hsu TC, Lee SC. 2008. Phosphorylation at Ser473 regulates heterochromatin protein 1 binding and corepressor function of TIF1beta/KAP1. BMC Mol. Biol. 9:61. doi:10.1186/1471-2199-9-61.
43. Anderson R, Wang S, Osiowy C, Issekutz AC. 1997. Activation of endothelial cells via antibody-enhanced dengue virus infection of peripheral blood monocytes. J. Virol.. 71:4226-4232.
44. Komanduri KV, Luce JA, McGrath MS, Herndier BG, Ng VL. 1996. The natural history and molecular heterogeneity of HIV-associated primary malignant lymphomatous effusions. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol.. 13:215-226.
45. Renne R, Zhong W, Herndier B, McGrath M, Abbey N, Kedes D, Ganem D. 1996. Lytic growth of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) in culture. Nat. Med.. 2:342-346.
46. Stoecklin G, Stubbs T, Kedersha N, Wax S, Rigby WF, Blackwell TK, Anderson P. 2004. MK2-induced tristetraprolin:14-3-3 complexes prevent stress granule association and ARE-mRNA decay. EMBO J. 23:1313-1324.
47. Winzen R, Kracht M, Ritter B, Wilhelm A, Chen CY, Shyu AB, Muller M, Gaestel M, Resch K, Holtmann H. 1999. The p38 MAP kinase pathway signals for cytokine-induced mRNA stabilization via MAP kinase-activated protein kinase 2 and an AU-rich region-targeted mechanism. EMBO J.. 18:4969-4980.
48. Kedes DH, Lagunoff M, Renne R, Ganem D. 1997. Identification of the gene encoding the major latency-associated nuclear antigen of the Kaposi's sarcoma-associated herpesvirus. J. Clin. Invest.. 100:2606-2610.
49. Kamitani S, Togi S, Ikeda O, Nakasuji M, Sakauchi A, Sekine Y, Muromoto R, Oritani K, Matsuda T. 2011. Kruppel-associated boxassociated protein 1 negatively regulates TNF-alpha-induced NF-kappaB transcriptional activity by influencing the interactions among STAT3, p300, and NF-kappaB/p65. J. Immunol.. 187:2476-2483.
50. Anderson DR, Hegde S, Reinhard E, Gomez L, Vernier WF, Lee L, Liu S, Sambandam A, Snider PA, Masih L. 2005. Aminocyanopyridine inhibitors of mitogen activated protein kinase-activated protein kinase 2 (MK-2). Bioorg. Med. Chem. Lett.. 15:1587-1590.
51. Brinkmann MM, Glenn M, Rainbow L, Kieser A, Henke-Gendo C, Schulz TF. 2003. Activation of mitogen-activated protein kinase and NF-B pathways by a Kaposi's sarcoma-associated herpesvirus K15 membrane protein. J. Virol.. 77:9346-9358.
52. Sharma-Walia N, Krishnan HH, Naranatt PP, Zeng L, Smith MS, Chandran B. 2005. ERK1/2 and MEK1/2 induced by Kaposi's sarcomaassociated herpesvirus (human herpesvirus 8) early during infection of target cells are essential for expression of viral genes and for establishment of infection. J. Virol.. 79:10308-10329.
53. Smit MJ, Verzijl D, Casarosa P, Navis M, Timmerman H, Leurs R. 2002. Kaposi's sarcoma-associated herpesvirus-encoded G proteincoupled receptor ORF74 constitutively activates p44/p42 MAPK and Akt via Gi and phospholipase C-dependent signaling pathways. J. Virol. 76: 1744-1752.
54. Wang L, Damania B. 2008. Kaposi's sarcoma-associated herpesvirus confers a survival advantage to endothelial cells. Cancer Res. 68:4640-4648.
55. Boshoff C, Whitby D, Talbot S, Weiss RA. 1997. Etiology of AIDSrelated Kaposi's sarcoma and lymphoma. Oral Dis. 3(Suppl 1):S129- S132.
56. Ensoli B, Sturzl M. 1999. HHV-8 and multistep tumourigenesis. Trends Microbiol.. 7:310-312.
57. Frank DA, Mahajan S, Ritz J. 1997. B lymphocytes from patients with chronic lymphocytic leukemia contain signal transducer and activator of transcription (STAT) 1 and STAT3 constitutively phosphorylated on serine residues. J. Clin. Invest.. 100:3140-3148.
58. Qin HR, Kim HJ, Kim JY, Hurt EM, Klarmann GJ, Kawasaki BT, Duhagon Serrat MA, Farrar WL. 2008. Activation of signal transducer and activator of transcription 3 through a phosphomimetic serine 727 promotes prostate tumourigenesis independent of tyrosine 705 phosphorylation. Cancer Res.. 68:7736-7741.
59. Bromberg JF, Horvath CM, Besser D, Lathem WW, Darnell JE, Jr. 1998. Stat3 activation is required for cellular transformation by v-src. Mol. Cell. Biol.. 18:2553-2558.
60. Turkson J, Bowman T, Adnane J, Zhang Y, Djeu JY, Sekharam M, Frank DA, Holzman LB, Wu J, Sebti S, Jove R. 1999. Requirement for Ras/Rac1-mediated p38 and c-Jun N-terminal kinase signaling in Stat3 transcriptional activity induced by the Src oncoprotein. Mol. Cell. Biol.. 19:7519-7528.
61. Yang J, Chatterjee-Kishore M, Staugaitis SM, Nguyen H, Schlessinger K, Levy DE, Stark GR. 2005. Novel roles of unphosphorylated STAT3 in oncogenesis and transcriptional regulation. Cancer Res.. 65:939-947.
62. Yang J, Stark GR. 2008. Roles of unphosphorylated STATs in signaling. Cell Res.. 18:443-451.
63. Busch S, Renaud SJ, Schleussner E, Graham CH, Markert UR. 2009. mTOR mediates human trophoblast invasion through regulation of matrix-remodeling enzymes and is associated with serine phosphorylation of STAT3. Exp. Cell Res.. 315:1724-1733.
64. Chung J, Uchida E, Grammer TC, Blenis J. 1997. STAT3 serine phosphorylation by ERK-dependent and -independent pathways negatively modulates its tyrosine phosphorylation. Mol. Cell. Biol.. 17:6508-6516.
65. Jain N, Zhang T, Kee WH, Li W, Cao X. 1999. Protein kinase C delta associates with and phosphorylates Stat3 in an interleukin-6-dependent manner. J. Biol. Chem.. 274:24392-24400.
66. Lim CP, Cao X. 1999. Serine phosphorylation and negative regulation of Stat3 by JNK. J. Biol. Chem.. 274:31055-31061.
67. Lutticken C, Coffer P, Yuan J, Schwartz C, Caldenhoven E, Schindler C, Kruijer W, Heinrich PC, Horn F. 1995. Interleukin-6-induced serine phosphorylation of transcription factor APRF: evidence for a role in interleukin-6 target gene induction. FEBS Lett.. 360:137-143.
68. Yokogami K, Wakisaka S, Avruch J, Reeves SA. 2000. Serine phosphorylation and maximal activation of STAT3 during CNTF signaling is mediated by the rapamycin target mTOR. Curr. Biol.. 10:47-50.
69. Denes A, Humphreys N, Lane TE, Grencis R, Rothwell N. 2010. Chronic systemic infection exacerbates ischemic brain damage via a CCL5 (regulated on activation, normal T-cell expressed and secreted)-mediated proinflammatory response in mice. J. Neurosci.. 30:10086-10095.
70. Suffee N, Hlawaty H, Meddahi-Pelle A, Maillard L, Louedec L, Haddad O, Martin L, Laguillier C, Richard B, Oudar O, Letourneur D, Charnaux N, Sutton A. 2012. RANTES/CCL5-induced pro-angiogenic effects depend on CCR1, CCR5 and glycosaminoglycans. Angiogenesis 15:727-744.
71. Suffee N, Richard B, Hlawaty H, Oudar O, Charnaux N, Sutton A. 2011. Angiogenic properties of the chemokine RANTES/CCL5. Biochem. Soc. Trans.. 39:1649-1653.
72. Zernecke A, Shagdarsuren E, Weber C. 2008. Chemokines in atherosclerosis: an update. Arterioscler. Thromb. Vasc. Biol.. 28:1897-1908.
73. Wang HW, Trotter MW, Lagos D, Bourboulia D, Henderson S, Makinen T, Elliman S, Flanagan AM, Alitalo K, Boshoff C. 2004. Kaposi sarcoma herpesvirus-induced cellular reprogramming contributes to the lymphatic endothelial gene expression in Kaposi sarcoma. Nat. Genet.. 36:687-693.
74. Loetscher P, Seitz M, Clark-Lewis I, Baggiolini M, Moser B. 1996. Activation of NK cells by CC chemokines. Chemotaxis, Ca2+ mobilization, and enzyme release. J. Immunol.. 156:322-327.
75. Schall TJ, Bacon K, Toy KJ, Goeddel DV. 1990. Selective attraction of monocytes and T lymphocytes of the memory phenotype by cytokine RANTES. Nature. 347:669-671.
76. Rot A, Krieger M, Brunner T, Bischoff SC, Schall TJ, Dahinden CA. 1992. RANTES and macrophage inflammatory protein 1 alpha induce the King migration and activation of normal human eosinophil granulocytes. J. Exp. Med.. 176:1489-1495.
77. Dieu MC, Vanbervliet B, Vicari A, Bridon JM, Oldham E, Ait-Yahia S, Briere F, Zlotnik A, Lebecque S, Caux C. 1998. Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites. J. Exp. Med.. 188:373-386.
78. Barcelos LS, Coelho AM, Russo RC, Guabiraba R, Souza AL, Bruno-Lima G, Jr, Proudfoot AE, Andrade SP, Teixeira MM. 2009. Role of the chemokines CCL3/MIP-1 alpha and CCL5/RANTES in sponge-induced inflammatory angiogenesis in mice. Microvasc. Res.. 78:148-154.
79. Ishida Y, Kimura A, Kuninaka Y, Inui M, Matsushima K, Mukaida N, Kondo T. 2012. Pivotal role of the CCL5/CCR5 interaction for recruitment of endothelial progenitor cells in mouse wound healing. J. Clin. Invest.. 122:711-721.
80. Soltoff SP. 2007. Rottlerin: an inappropriate and ineffective inhibitor of PKCdelta. Trends Pharmacol. Sci.. 28:453-458.
81. Blasius M, Forment JV, Thakkar N, Wagner SA, Choudhary C, Jackson SP. 2011. A phospho-proteomic screen identifies substrates of the checkpoint kinase Chk1. Genome Biol. 12:R78. doi:10.1186/gb-2011-12-8-r78.
82. Reinhardt HC, Aslanian AS, Lees JA, Yaffe MB. 2007. p53-deficient cells rely on ATM-and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage. Cancer Cell. 11:175-189.
83. Reinhardt HC, Yaffe MB. 2009. Kinases that control the cell cycle in response to DNA damage: Chk1, Chk2, and MK2. Curr. Opin. Cell Biol.. 21:245-255.
84. Chang PC, Fitzgerald LD, Van Geelen A, Izumiya Y, Ellison TJ, Wang DH, Ann DK, Luciw PA, Kung HJ. 2009. Kruppel-associated box domain-associated protein-1 as a latency regulator for Kaposi's sarcomaassociated herpesvirus and its modulation by the viral protein kinase. Cancer Res.. 69:5681-5689.
85. Franses JW, Baker AB, Chitalia VC, Edelman ER. 2011. Stromal endothelial cells directly influence cancer progression. Sci. Transl. Med. 3:66ra65. doi:10.1126/scitranslmed.3001542.
86. Kim SS, Chen YM, O'Leary E, Witzgall R, Vidal M, Bonventre JV. 1996. A novel member of the RING finger family, KRIP-1, associates with the KRAB-A transcriptional repressor domain of zinc finger proteins. Proc. Natl. Acad. Sci. U. S. A.. 93:15299-152304.
87. Agata Y, Matsuda E, Shimizu A. 1999. Two novel Krüppel-associated box-containing zinc-finger proteins, KRAZ1 and KRAZ2, repress transcription through functional interaction with the corepressor KAP-1 (TIF1beta/KRIP-1). J. Biol. Chem.. 274:16412-16422.